SCHEMBL2919121

SCHEMBL2919121

COc1ccc(-n2nc(C(=O)N3CC(C)N(C)C(C)C3)cc2-c2ccccn2)cn1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
NTRK1 P04629 7/20 0.39
CFTR P13569 2/20 0.38
MGLL Q99685 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
PDK2 Q15119 1/20 0.36
SCD O00767 2/20 0.36
SCD5 Q86SK9 2/20 0.36
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
PIK3R5 Q8WYR1 1/20 0.35
PIK3R3 Q92569 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2918346 0.91 CFTR (0.42) HCRTR1HCRTR2NTRK1CFTRMGLL
SCHEMBL2916328 0.89 BRD4 (0.41) HCRTR1HCRTR2NTRK1MGLLPDK2
SCHEMBL2918416 0.88 RPA1 (0.47) MGLL
SCHEMBL2917841 0.88 MALT1 (0.44) HCRTR1HCRTR2NTRK1MGLLSCD
SCHEMBL5268929 0.86 MGLL (0.38) HCRTR1HCRTR2NTRK1MGLLSMN1; SMN2
SCHEMBL2919855 0.86 MGLL (0.50) NTRK1CFTRMGLLPIK3CDPIK3R2
SCHEMBL13637539 0.85 MALT1 (0.45) CFTRMGLLSMN1; SMN2PIK3CDPIK3R2
SCHEMBL5270015 0.85 NTRK1 (0.43) NTRK1MGLLSCD5
SCHEMBL2919136 0.84 NTRK1 (0.45) NTRK1CFTRMGLLPIK3CDPIK3R2
SCHEMBL2910146 0.84 CFTR (0.44) CFTRMGLLPIK3CDPIK3R2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 HCRTR1 4367/4885HCRTR2 3668/4885NTRK1 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.